Human platelet antigens-2013

被引:112
作者
Curtis, B. R. [1 ]
McFarland, J. G. [1 ]
机构
[1] BloodCtr Wisconsin, Platelet & Neutrophil Immunol Lab, Milwaukee, WI 53201 USA
关键词
neonatal alloimmune thrombocytopenia; platelet antigens; platelet refractoriness; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; BLOOD-GROUP-A; FLUORESCENCE FLOW-CYTOMETRY; SINGLE-POINT MUTATION; CLASS-I HLA; GLYCOPROTEIN-IIIA; FETOMATERNAL ALLOIMMUNIZATION; TRANSFUSION REFRACTORINESS; POTENTIAL PREDICTOR; ALPHA(2) INTEGRIN;
D O I
10.1111/vox.12085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To date, 33 human platelet alloantigens (HPAs) have been identified on six functionally important platelet glycoprotein (GP) complexes and have been implicated in alloimmune platelet disorders including foetal and neonatal alloimmune thrombocytopenia (FNAIT), posttransfusion purpura (PTP) and multitransfusion platelet refractoriness (MPR). The greatest number of recognized HPA (20 of 33) resides on the GPIIb/IIIa complex, which serves as the receptor for ligands important in mediating haemostasis and inflammation. These include HPA-1a, the most commonly implicated HPA in FNAIT and PTP in Caucasian populations. Other platelet GP complexes, GPIb/V/IX, GPIa/IIa and CD109, express the remaining 13 HPAs. Of the recognized HPAs, 12 occur as six serologically and genetically defined biallelic systems' where the -a form designates the higher frequency allele and the -b form, the lower. Twenty-one other HPAs are low-frequency or rare antigens for which postulated higher frequency -a alleles have not yet been identified as antibody specificities. In addition to the HPA markers, platelets also express ABO and human leucocyte antigen (HLA) antigens; antibodies directed at the former are occasionally important in FNAIT, and to the latter, in MPR.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 99 条
  • [61] McGann M J, 2000, Immunohematology, V16, P68
  • [62] Nomenclature of human platelet antigens
    Metcalfe, P
    Watkins, NA
    Ouwehand, WH
    Kaplan, C
    Newman, P
    de Haas, M
    Aster, R
    Shibata, Y
    Smith, J
    Kiefel, V
    Santoso, S
    [J]. VOX SANGUINIS, 2003, 85 (03) : 240 - 245
  • [63] Mohabir L A, 1997, Immunohematology, V13, P44
  • [64] MUELLERECKHARDT C, 1989, LANCET, V1, P363
  • [65] NORIS P, 1995, BLOOD, V86, P1019
  • [66] Prevention and management of platelet transfusion refractoriness
    Novotny, VMJ
    [J]. VOX SANGUINIS, 1999, 76 (01) : 1 - 13
  • [67] Inherited platelet disorders
    Nurden, A. T.
    Freson, K.
    Seligsohn, U.
    [J]. HAEMOPHILIA, 2012, 18 : 154 - 160
  • [68] Congenital disorders associated with platelet dysfunctions
    Nurden, Paquita
    Nurden, Alan T.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 253 - 263
  • [69] OGASAWARA K, 1993, BLOOD, V82, P993
  • [70] Fetal and Neonatal Alloimmune Thrombocytopenia A Management Algorithm Based on Risk Stratification
    Pacheco, Luis D.
    Berkowitz, Richard L.
    Moise, Kenneth J., Jr.
    Bussel, James B.
    McFarland, Janice G.
    Saade, George R.
    [J]. OBSTETRICS AND GYNECOLOGY, 2011, 118 (05) : 1157 - 1162